Pava Partners advised the sole shareholder of Aplantis GmbH (“Aplantis”), Dr. Robert Gick, on the sale of the majority of the shares to Arcus Capital AG (“Arcus Capital“).

Aplantis is a highly specialized B2B full-service provider for the global sourcing of plant-based and biotechnologically produced raw materials. As a quality leader with an integrated warehouse and laboratory , Aplantis has established itself as a preferred partner for its growing customer base in the premium segment. Together with Arcus Capital, the planned national and international growth strategy is now to be implemented. Founder and CEO Dr. Robert Gick will remain with the company and will reinvest substantially.

Founded in 2018 and based in Weilheim near Munich, Aplantis operates in a highly dynamic and growing market characterized by constantly increasing quality demands and the megatrend of healthy and sustainable plant-based nutrition.

The company offers a unique product portfolio of complex plant-based and biotechnologically produced raw materials such as plant powders and extracts, medicinal mushrooms, marine products, fruit powders and enzymes, which are used in the food supplement, food, pet food and cosmetics industries. By conducting extensive product analysis in its own laboratory and affiliated third-party laboratories, Aplantis sets new standards in terms of quality and product safety.

As an entrepreneurial partner, Arcus Capital contributes industry know-how and portfolio synergies and will continue to successfully develop the company together with Aplantis’ management.

“We see a large and steadily growing market, which we can now vigorously develop with our new partner Arcus Capital. Pava Partners has prepared the process optimally with its excellent knowledge of our business and, thanks to its outstanding communication skills, has won this ideal partner for us. A big thank you to the entire team,” says founder and CEO Dr. Robert Gick.